vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and PAMT CORP (PAMT). Click either name above to swap in a different company.
PAMT CORP is the larger business by last-quarter revenue ($141.3M vs $139.2M, roughly 1.0× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -20.7%, a 56.2% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -15.1%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-25.0M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -12.0%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
ADMA vs PAMT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $141.3M |
| Net Profit | $49.4M | $-29.3M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | -27.0% |
| Net Margin | 35.5% | -20.7% |
| Revenue YoY | 18.4% | -15.1% |
| Net Profit YoY | -55.9% | 7.4% |
| EPS (diluted) | $0.20 | $-1.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $141.3M | ||
| Q3 25 | $134.2M | $150.3M | ||
| Q2 25 | $122.0M | $151.1M | ||
| Q1 25 | $114.8M | $155.3M | ||
| Q4 24 | $117.5M | $166.5M | ||
| Q3 24 | $119.8M | $182.6M | ||
| Q2 24 | $107.2M | $182.9M | ||
| Q1 24 | $81.9M | $182.6M |
| Q4 25 | $49.4M | $-29.3M | ||
| Q3 25 | $36.4M | $-5.6M | ||
| Q2 25 | $34.2M | $-9.6M | ||
| Q1 25 | $26.9M | $-8.1M | ||
| Q4 24 | $111.9M | $-31.6M | ||
| Q3 24 | $35.9M | $2.4M | ||
| Q2 24 | $32.1M | $-2.9M | ||
| Q1 24 | $17.8M | $281.0K |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | -27.0% | ||
| Q3 25 | 38.0% | -3.8% | ||
| Q2 25 | 35.1% | -7.3% | ||
| Q1 25 | 30.4% | -5.9% | ||
| Q4 24 | 32.6% | -22.6% | ||
| Q3 24 | 33.1% | 1.3% | ||
| Q2 24 | 36.6% | -0.4% | ||
| Q1 24 | 26.7% | -0.4% |
| Q4 25 | 35.5% | -20.7% | ||
| Q3 25 | 27.1% | -3.7% | ||
| Q2 25 | 28.1% | -6.4% | ||
| Q1 25 | 23.4% | -5.2% | ||
| Q4 24 | 95.2% | -19.0% | ||
| Q3 24 | 30.0% | 1.3% | ||
| Q2 24 | 29.9% | -1.6% | ||
| Q1 24 | 21.7% | 0.2% |
| Q4 25 | $0.20 | $-1.38 | ||
| Q3 25 | $0.15 | $-0.27 | ||
| Q2 25 | $0.14 | $-0.46 | ||
| Q1 25 | $0.11 | $-0.37 | ||
| Q4 24 | $0.45 | $-1.44 | ||
| Q3 24 | $0.15 | $0.11 | ||
| Q2 24 | $0.13 | $-0.13 | ||
| Q1 24 | $0.08 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $83.7M |
| Total DebtLower is stronger | $72.1M | $333.9M |
| Stockholders' EquityBook value | $477.3M | $210.5M |
| Total Assets | $624.2M | $697.9M |
| Debt / EquityLower = less leverage | 0.15× | 1.59× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $83.7M | ||
| Q3 25 | $61.4M | $115.6M | ||
| Q2 25 | $90.3M | $117.3M | ||
| Q1 25 | $71.6M | $102.7M | ||
| Q4 24 | $103.1M | $110.7M | ||
| Q3 24 | $86.7M | $92.3M | ||
| Q2 24 | $88.2M | $114.0M | ||
| Q1 24 | $45.3M | $125.8M |
| Q4 25 | $72.1M | $333.9M | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | $325.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $210.5M | ||
| Q3 25 | $431.2M | $239.5M | ||
| Q2 25 | $398.3M | $244.9M | ||
| Q1 25 | $373.4M | $269.6M | ||
| Q4 24 | $349.0M | $277.5M | ||
| Q3 24 | $231.9M | $308.9M | ||
| Q2 24 | $188.3M | $306.7M | ||
| Q1 24 | $153.7M | $314.6M |
| Q4 25 | $624.2M | $697.9M | ||
| Q3 25 | $568.7M | $715.2M | ||
| Q2 25 | $558.4M | $707.9M | ||
| Q1 25 | $510.6M | $712.6M | ||
| Q4 24 | $488.7M | $741.7M | ||
| Q3 24 | $390.6M | $756.7M | ||
| Q2 24 | $376.4M | $733.5M | ||
| Q1 24 | $350.9M | $746.4M |
| Q4 25 | 0.15× | 1.59× | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 1.17× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-5.8M |
| Free Cash FlowOCF − Capex | $34.6M | $-25.0M |
| FCF MarginFCF / Revenue | 24.8% | -17.7% |
| Capex IntensityCapex / Revenue | 0.8% | 13.6% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-23.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-5.8M | ||
| Q3 25 | $13.3M | $5.9M | ||
| Q2 25 | $21.1M | $12.2M | ||
| Q1 25 | $-19.7M | $5.0M | ||
| Q4 24 | $50.2M | $15.2M | ||
| Q3 24 | $25.0M | $15.5M | ||
| Q2 24 | $45.6M | $18.7M | ||
| Q1 24 | $-2.2M | $9.6M |
| Q4 25 | $34.6M | $-25.0M | ||
| Q3 25 | $-1.1M | $2.5M | ||
| Q2 25 | $18.7M | $5.9M | ||
| Q1 25 | $-24.4M | $-6.8M | ||
| Q4 24 | $47.5M | $-39.9M | ||
| Q3 24 | $24.0M | $-33.6M | ||
| Q2 24 | $43.6M | $4.1M | ||
| Q1 24 | $-4.6M | $-12.2M |
| Q4 25 | 24.8% | -17.7% | ||
| Q3 25 | -0.8% | 1.7% | ||
| Q2 25 | 15.3% | 3.9% | ||
| Q1 25 | -21.2% | -4.4% | ||
| Q4 24 | 40.4% | -24.0% | ||
| Q3 24 | 20.0% | -18.4% | ||
| Q2 24 | 40.7% | 2.2% | ||
| Q1 24 | -5.6% | -6.7% |
| Q4 25 | 0.8% | 13.6% | ||
| Q3 25 | 10.7% | 2.3% | ||
| Q2 25 | 2.0% | 4.2% | ||
| Q1 25 | 4.1% | 7.6% | ||
| Q4 24 | 2.3% | 33.1% | ||
| Q3 24 | 0.9% | 26.9% | ||
| Q2 24 | 1.9% | 8.0% | ||
| Q1 24 | 2.9% | 12.0% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 6.44× | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | 34.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
PAMT
| Freight Transportation Service | $123.1M | 87% |
| Fuel Surcharge | $18.2M | 13% |
